Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
St. Jude Children's Research Hospital
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07226219CT.gov Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease | — | Recruiting | — | — | — |
NCT05561205CT.gov rTMS for Apathy Clinical Trial | — | Recruiting | — | — | — |
NCT02326038CT.gov Ritalin, Memory and Attention in MCI: a Behaviour-EEG Study | — | Unknown | — | — | — |
NCT02225106CT.gov Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI | — | Completed | — | — | — |
NCT02178995CT.gov Methylphenidate Treatment of Attention Deficits in Epilepsy | — | Completed | — | — | — |
NCT02098824CT.gov Symptomatic Treatment of Vascular Cognitive Impairment | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cognitive Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Methylphenidate (this asset) | St. Jude Children's Research Hospital | Approved | BB · 66 |
| Nicotine | University of Southern California | P2 | BBB |
| Oxybutynin | University of Alberta | P4 | BBB |
| Metformin | Fudan University | P4 | BB |
| Rivastigmine | VA Office of Research and Development | P4 | BB |
| Levodopa | Vanderbilt University Medical Center | P4 | BB |
| Ginkgo Biloba | Dr. Willmar Schwabe GmbH & Co. KG | P4 | BB |
| Memantine | UNC Lineberger Comprehensive Cancer Center | P3 | BB |
| Egb 761® | Ipsen | P4 | BB |
+42 more in the Cognitive Disorder cohort
Other indications for Methylphenidate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Attention Deficit-Hyperactivity Disorder | — | P4 | BBB · 76 |
| Multiple Sclerosis | — | P3 | BB · 70 |
| Alzheimer Disease | — | P4 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Methylphenidate in Cognitive Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/methylphenidate-cognitive-disorder-1332
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →